
Sign up to save your podcasts
Or


The gene-editing therapy, called Casgevy, uses Crispr to prevent debilitating pain in patients with sickle cell disease. It also eliminates the need for regular blood transfusions in people with beta thalassemia.
Read this story here.
By WIRED4.3
5656 ratings
The gene-editing therapy, called Casgevy, uses Crispr to prevent debilitating pain in patients with sickle cell disease. It also eliminates the need for regular blood transfusions in people with beta thalassemia.
Read this story here.

4,008 Listeners

26,388 Listeners

9,490 Listeners

482 Listeners

100 Listeners

50 Listeners

87,159 Listeners

112,433 Listeners

60 Listeners

24,235 Listeners

77 Listeners

5,475 Listeners

398 Listeners

29,130 Listeners

16,083 Listeners

2,278 Listeners

3,423 Listeners